Clinical Trials in Nashville

Showing 5301-5320 of 15,379 trials

Investigation of Genetic Determinants of Capecitabine Toxicity

NCT00977119

The purpose of this study is to identify possible genetic polymorphisms that contribute to specific toxicities associated with capecitabine (hand-foot syndrome, diarrhea, and neutropenia). Additionally, this study will look at gene polymorphisms in patients experiencing the toxicities of interest, the frequency of polymorphisms and differences in drug metabolism.

Breast Cancer

University of Chicago240 participantsStarted Nov 2009

Birmingham, Alabama, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +10 more locations

COMPLETEDPhase 1< 1 mile

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

NCT02443324

The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), transitional cell carcinoma of the urothelium, or biliary tract cancer (BTC).

Gastric AdenocarcinomaAdenocarcinoma of the Gastroesophageal JunctionNon-small Cell Lung Cancer+2 more

Eli Lilly and Company175 participantsStarted Jul 2015

New Haven, Connecticut, United States • Fort Myers, Florida, United States • St. Petersburg, Florida, United States +19 more locations

Investigation of Genetic Determinants of Capecitabine Toxicity

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Find Trials by Condition in Nashville

Reducing Sedentary Time in Patients With Cardiovascular Disease

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

Episealer® Knee System IDE Clinical Study

A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Adjunct Collection of Additional Biorepository Data From Patients Enrolled in Diabetic Foot Consortium (DFC) Trials

RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years

Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary

Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)